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Background
Mithramycin (MTR), a clinically approved DNA-binding
antitumor antibiotic has been found to cross the blood-
brain barrier and is in its preclinical trials in Huntington’s
disease (HD) [1]. It improved altered nucleosome homeos-
tasis in HD mice, normalizing the chromatin pattern. It
has the ability to rebalance epigenetic histone modifica-
tions. The binding properties of MTR with histone pro-
teins have been examined from the perspective of the
current proposition from our laboratory to classify small
DNA binding molecules in terms of their ability to bind
chromosomal DNA alone (single binding mode) or both
histones and chromosomal DNA (dual binding mode)
[2,3].
Materials and methods
Chemicals were from Sigma, histones from New Eng-
land Biolabs, antibodies from Abacm, Active Motif.
Spectrofluorimetry, circular dichroism (CD) studies, in
vitro histone acetyl transferase (HAT) assay and western
blot analysis were employed as experimental tools.
Results
Spectrofluorimetric measurements and CD studies show
that MTR binds with micromolar dissociation constant to
core histone assembly and its individual histone compo-
nents. A single isoelliptic point in the CD spectra indicates
formation of one type of complex between MTR and his-
tones. Complex formation leads to decrease in molar ellip-
ticity in the far UV CD spectra of core histones. These
results led us to investigate the role of MTR as a potential
epigenetic modulator. In vitro HAT assays using CREB-
binding protein (CBP) HAT domain, a transcriptional
coactivator, showed that MTR inhibits H3 K18 acetylation
(specifically mediated mark by CBP/p300 in vivo) in H3.3
recombinant histone whereas it induces H3 K18 hyperace-
tylation in H3.1/H4 tetramer as well as core histones.
Conclusions
MTR exhibits dual binding mode since it binds to histone
proteins present in chromatin besides DNA [4]. It alters
CBP induced H3 K18 acetylation. In contrast to MTR-
DNA interaction, association of MTR with histones does
not require obligatory presence of bivalent metal ions. The
interaction of MTR with histones hints at a different sce-
nario in MTR-chromatin interaction. Experiments are in
progress to address the effect of MTR on other epigenetic
marks. The significance of these in vitro experiments
would also be examined by performing cell line based
experiments. These data would be useful in understanding
the mechanism of action of anticancer drugs as well as in
designing new-generation therapeutics.
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